2026-10-14

Next Day Disclosure Return

2026-10-13

Next Day Disclosure Return

2026-10-06

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026

2026-09-29

Next Day Disclosure Return

2026-09-28

VOLUNTARY ANNOUNCEMENT - COMPLETION OF CAPITAL INCREASE OF A SUBSIDIARY

2026-09-28

2026 Interim Report

2026-09-16

Next Day Disclosure Return

2026-09-11

Next Day Disclosure Return

2026-09-10

Next Day Disclosure Return

2026-09-04

Next Day Disclosure Return

2026-09-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August, 2026

2026-08-28

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

2026-08-28

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

2026-08-27

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT OF ADVANCED HCC

2026-08-27

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT OF ADVANCED HCC

2026-08-26

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

2026-08-26

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

2026-08-25

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003

2026-08-25

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003

2026-08-21

VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE FDA